News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aurinia (ISA.TO) Initiates Phase 2b Clinical Trial Of Voclosporin To Treat Lupus Nephritis


6/26/2014 7:24:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VICTORIA, British Columbia, June 26, 2014 (GLOBE NEWSWIRE) -- Aurinia Pharmaceuticals, Inc., (TSX-V:AUP) today announced enrollment of the first patient in its planned Phase 2b clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition. The Lupus Foundation of America believes there are as many as 1.5 million people in the U.S. with systemic lupus erythematosus (SLE), approximately 40 to 70 percent of whom will develop LN.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES